News Daily News Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding L.A. McKeown May 16, 2025
News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Conference News ESC 2023 ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients L.A. McKeown August 30, 2023
News Daily News OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer L.A. McKeown December 16, 2022
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Daily News Initiative Lowers Unnecessary Aspirin Use in Warfarin Users Todd Neale September 26, 2022
News Daily News DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis L.A. McKeown January 20, 2022
News Daily News Shorter Anticoagulation an Option for Young Patients With Provoked VTE Todd Neale January 11, 2022
News Daily News FDA Approves Two Additional Indications for Rivaroxaban in Children L.A. McKeown December 21, 2021
News Daily News Long-term Anticoagulation After Unprovoked VTE: New Insights Shelley Wood September 13, 2021
News Daily News ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE Todd Neale December 22, 2020
News Daily News Rivaroxaban May Yet Protect After a Hospital Stay: MARINER Caitlin E. Cox June 25, 2020
News Conference News ACC 2020 Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients L.A. McKeown April 01, 2020
News Conference News ESC 2019 ESC Updates Guidance on Management of Acute Pulmonary Embolism Todd Neale September 06, 2019